Wednesday, February 28, 2024
Aria CV has announced a significant development in the treatment of pulmonary hypertension with the successful implantation of the Gen 2 Aria CV Pulmonary Hypertension System in the ASPIRE PH clinical trial at the Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana. This innovative system involves the insertion of an implantable gas-filled balloon into the main pulmonary artery through percutaneous means.
Its primary function is to alleviate the strain on the right heart, which can lead to right heart failure. The Aria device aims to mimic the benefits of a healthy pulmonary artery by reducing cardiac workload and enhancing blood flow through the lungs. This achievement marks a significant step forward in Aria CV's mission to improve the lives of individuals suffering from pulmonary hypertension, a condition that can have life-threatening consequences if left untreated.
The ASPIRE PH trial, conducted under the FDA's Early Feasibility Study Program, assesses the safety, tolerability, and efficacy of the Aria System. Pending approval, this technology holds promise for transforming the treatment landscape for pulmonary hypertension patients, offering a potential lifeline to those affected by this progressive and often deadly disease. Pulmonary hypertension affects millions worldwide, characterized by elevated blood pressure in the lung arteries and a heightened risk of right heart failure. It can arise from various underlying conditions, including COPD and left heart failure, and is recognized as a serious and progressive illness.
Source: businesswire.com
